"imagine if you could print entire organs and grown from samples of your own body tissue. Organovo (ONVO) has developed a bio-printer that uses human cells instead of ink to create living 3-dimensional structures. It is no surprise that Organovo was listed as one of the fifty most innovative companies in 2012 by the MIT Technology Review.
In all likelihood, product development will happen in three stages. The first stage will be human-like body tissues for drug toxicity testing. The second will be simple tissues for implant (cardiac patches, skin, or arteries). The final goal of manufacturing fully functional organs is years away, but the potential impact for the health care industry is simply mind-blowing.
The problem with Organovo’s business is that it is bleeding cash. This usually leads to shareholder dilution, so investors need to think of this as a very high-risk, very long-term proposition